A new study presented at ADLM 2026 shows a high-sensitivity biosensor can quantify the ESAT-6 protein in blood, distinguishing active tuberculosis from latent infection and other lung diseases.
Scientists have taken a major step toward developing a blood test that could identify millions of people who spread tuberculosis unknowingly.
A research team discovered new technology that will quickly and easily detect active Mycobacterium tuberculosis (TB) infection antibodies.
FIND and Cepheid are launching the Xpert MTB/XDR test, which enables expanded drug-resistance tuberculosis (TB) profiling in less than 90 minutes.
Read More
NanoPin’s diagnostic platform using Thermo Fisher’s advanced LC-MS technology will create sensitive clinical assays for infectious disease.
Read More
The test enables highly automated screening for latent tuberculosis.
Read More
IGeneX’s new BCA assays are simple and cost-effective tests that give either a positive or negative result for exposure to Borrelia spp.
Read More
Positive and negative controls are designed to help laboratories deliver reliable MTB-RIF testing results.
Read MoreThe funding will enable Lophius to expand clinical performance data and finalize design of the assay for use on automated platforms.
Read MoreSeries C funding will finance further development and CE marking of the company’s first molecular point-of-care platform based on pulse-controlled amplification technology.
Read More
Access to innovative diagnostic solutions will contribute to the World Health Organization’s infectious disease elimination goals.
Read More
Study data show that the metabolic sensor mTOR contributes on the genetic level to the development of sarcoidosis.
Read More
Continued validation of Lophius’ development capabilities bodes well as the company advances into tuberculosis diagnostics as its next focus area.
Read More
The BD Max MDR-TB panel has obtained the CE mark, supporting market launch in Europe.
Read More
Protecting sample stability ensures the utility of the latest generation of TB tests.
Read More
The analytic visualization tool can be used to discover, grade, and track key bacterial drug-resistance mutations.
Read More
The landmark NIH study represents a major advance in tuberculosis research.
Read MoreCepheid has signed a memorandum of understanding representing its intention to work with USAID to support the White House’s national action plan for combating MDR-TB.
Read More